foxo4-dri senolytic peptide baar 2017 cell Frontiers Senolytics: charting a new course
Senolytics: charting a new course or enhancing existing anti tumor therapies? Cellular Oncology Springer Nature Link Cellular Senescence in Health, Disease, and Lens Aging Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells eBioMedicine The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications
Pay in 4 interest-free payments of $6.11 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5



